Clinical trial · no report yet · Phase 3
De-ESCALaTE
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
- NCT01874171 ↗
- Unknown
- University of Warwick
- 25 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| Podcasts | 8 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Cisplatin; Cetuximab
- Arms
- Cisplatin · Active comparator
- Cetuximab · Experimental
- Enrollment
- 334
- Primary outcomes
- Compare severe (acute and late) toxicity (Grade 3-5) caused by cetuximab and radiotherapy to that caused by cisplatin and radiotherapy.
- Sponsor
- University of Warwick with Cancer Research UK, University of Birmingham, University of Oxford
- Start
- Nov 15, 2012
- Primary completion
- Feb 2019 (estimated)
- Results posted
- No
- Registry record
- NCT01874171 · updated May 8, 2017